|
Albuquerque,
NM (March 2, 2010) -Biomoda, Inc. (OTC BB: BMOD) (www.biomoda.com)
was today awarded U.S. patent 7,670,799, entitled,
"Composition and Method for Making 5, 10, 15, 20- Tetrakis
(Carboxyphenyl) Porphine (TCPP)" directed to Biomoda's
proprietary TCPP formulation for cancer and pre-cancer cell
identification and analysis and a method of making the TCPP
formulation.
"This
new patent further strengthens and secures Biomoda's market
position for early cancer detection," said John Cousins,
Biomoda's President. "It reflects the continuing and
successful research and development that is an essential part of
our Company."
Biomoda's
patented cancer and pre-cancer cell based diagnostic assay is
trademarked under the name CyPath®. Patent 7,670,799
together with Biomoda's U.S. patents 6,838,248, entitled
"Compositions and Methods for Detecting Pre-Cancerous
Conditions in Cell and Tissue Samples Using 5, 10, 15, 20-Tetrakis
(Carboxyphenyl) Porphine" and 7,384,764, entitled
"Methods for Prognosing Response to Cancer Therapy with 5,
10, 15, 20-Tetrakis (Carboxyphenyl) Porphine" protect the
method of detecting cancerous conditions and prognosing responses
to cancer therapy with TCPP.
The
TCPP platform is the foundation for CyPath®, an in-vitro test for
the detection of early-stage lung cancer that currently is
completing Phase II clinical trials. Study volunteers have
provided deep-lung sputum samples to be screened for cancer with
the CyPath® assay in the Biomoda laboratory. Results are
compared to CT scans and Pap stains read by independent
radiologists and cytopathologists, respectively, to confirm
accuracy.
Biomoda
is seeking Food and Drug Administration (FDA) approval of CyPath®,
its cytology-based screening technology as a Class III medical
device. Multi-site Phase III trials, the final step before
FDA approval, are scheduled to begin in 2010.
About
Biomoda
Biomoda
(OTC BB: BMOD) (www.biomoda.com)
is a cancer diagnostics company focused on the development of
accurate, inexpensive and noninvasive tests for the early
detection of cancer. Current research and development operations,
laboratory functions for both microscopy and assay formulation,
and administrative offices are located in Albuquerque, NM.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are based on
estimates, projections, beliefs and assumptions of Biomoda
management at the time of such statements and are not guarantees
of future performance. Forward-looking statements involve risks
and uncertainties in predicting future results and conditions.
Actual results could differ materially from those projected in
these forward-looking statements due to a variety of factors,
including, without limitation, the acceptance by customers of our
products, our ability to develop new products cost-effectively,
our ability to raise capital in the future, the development by
competitors of products using improved or alternative technology,
the retention of key employees and general economic conditions.
Forward-looking statements are made as of the date of this press
release and are subject to change without notice.
CONTACT:
Biomoda, Inc.
John
Cousins
505.821.0875
investor@biomoda.com
|
